Stay updated on Empagliflozin in Heart Failure Clinical Trial

Sign up to get notified when there's something new on the Empagliflozin in Heart Failure Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Empagliflozin in Heart Failure Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    Added a Locations section with the Connecticut site for the EMPA trial and removed the HHS Vulnerability Disclosure footer link and the older Connecticut Locations listing.
    Difference
    0.2%
    Check dated 2025-12-23T20:37:22.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    27 days ago
    No Change Detected
  5. Check
    41 days ago
    Change Detected
    Summary
    The Publications note was updated to indicate PubMed auto-filling, and the page revision was updated from v3.2.0 to v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-24T21:05:00.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    The notice about government funding-related data delays and operating status has been removed from the page. This removes guidance on data timeliness during funding lapses.
    Difference
    0.4%
    Check dated 2025-11-17T18:23:48.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The new screenshot shows only visual/layout adjustments without changes to core study content, eligibility criteria, enrollment, or results; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-11-03T12:53:08.000Z thumbnail image
  8. Check
    91 days ago
    Change Detected
    Summary
    Summary: The page now displays a funding-status notice and announces a major version upgrade to v3.2.0, replacing the previous v3.1.0.
    Difference
    4%
    Check dated 2025-10-05T17:38:16.000Z thumbnail image
  9. Check
    99 days ago
    Change Detected
    Summary
    Added version label v3.1.0 and removed several drug-safety topics (drug safety, counterfeit drugs, pharmaceutical preparations, substandard drugs) along with a previous version label v3.0.2; indicates a content reorganization and potential narrowing of safety topics.
    Difference
    0.5%
    Check dated 2025-09-28T11:13:03.000Z thumbnail image

Stay in the know with updates to Empagliflozin in Heart Failure Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Empagliflozin in Heart Failure Clinical Trial page.